Company Focus
Moderna
Latest Moderna News
Biotechnology
The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna and BioNTech generating momentum and sharpening investor focus. 23 July 2025
Related News
Insights
Company Spotlight
A Swiss biotech company focussed on antibody discovery and development.
Latest News & Features of interest to Moderna
Pharmaceutical
Privately-held Spanish CNS specialist Minoryx Therapeutics and Germany’s Neuraxpharm Group today announced that the marketing authorization application (MAA) for Minoryx’ lead candidate Nezglyal (leriglitazone) has been submitted to the European Medicines Agency (EMA) for the treatment of pediatric and adult male patients with cerebral adrenoleukodystrophy (cALD). 23 July 2025
Biotechnology
Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. 23 July 2025
Biotechnology
Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant. 23 July 2025
Biotechnology
Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ Immunobody DNA active immunotherapies in combination with checkpoint inhibitors in advanced unresectable melanoma. 23 July 2025
Pharmaceutical
French pharma Ipsen (Euronext: IPN) today announced the following changes to its executive committee: 23 July 2025
Biotechnology
Shares in Replimune Group, a US biotech developing novel oncolytic immunotherapies, went in freefall Tuesday, as the company announced a major setback. 22 July 2025
Biotechnology
US biotech iTeos Therapeutics yesterday announced that it has entered into a definitive merger agreement Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, this year, which has already come to the rescue of five struggling biotechs. 22 July 2025
Biotechnology
Shares in Sarepta Therapeutics have slumped by more than a third since late last week amid new updates on its gene therapy development woes. 22 July 2025
Biotechnology
Canadian biotech Eyam Health has entered a research alliance with Swiss-based nonprofit Medicines for Malaria Venture to explore monoclonal antibody-based therapies aimed at preventing malaria. 22 July 2025
Pharmaceutical
George Medicines, a UK biopharma focused on cardiometabolic diseases, has entered into an exclusive licensing and supply agreement with Azurity Pharmaceuticals. a privately-held US pharma. 21 July 2025
Latest In Brief for Moderna
Biotechnology
Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics. 3 July 2025
Latest Relevant Ones To Watch News
US biotech iTeos Therapeutics yesterday announced that it has entered into a definitive merger agreement Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, this year, which has already come to the rescue of five struggling biotechs. 22 July 2025
30 June 2025
17 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze